CVE:BCT

BriaCell Therapeutics Competitors

C$4.00

-0.50 (-11.11 %)

(As of 04/14/2021 03:58 PM ET)

Add

Compare

Today's Range

C$4.00

Now: C$4.00▼

C$4.41

50-Day Range

C$4.08

MA: C$4.85▼

C$8.00

52-Week Range

C$3.70

Now: C$4.00▼

C$14.00

Volume47,271 shs

Average Volume10,068 shs

Market CapitalizationC$3.09 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

BriaCell Therapeutics (CVE:BCT) Vs. CTX, KNE, GSD, PAS, NSP, and MPH

Should you be buying BCT stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to BriaCell Therapeutics, including Crescita Therapeutics (CTX), Kane Biotech (KNE), Devonian Health Group (GSD), Pascal Biosciences (PAS), Naturally Splendid Enterprises (NSP), and Medicure (MPH).

BriaCell Therapeutics vs. Crescita Therapeutics Stock

Crescita Therapeutics (TSE:CTX) and BriaCell Therapeutics (CVE:BCT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Earnings and Valuation

This table compares Crescita Therapeutics and BriaCell Therapeutics' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescita Therapeutics	C$15.64 million	1.11	C$41,296.00	C$0.00	420.00
BriaCell Therapeutics	N/A	N/A	N/A	C($3.10)	-1.29

Crescita Therapeutics has higher revenue and earnings than BriaCell Therapeutics. BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Crescita Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Crescita Therapeutics and BriaCell Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Crescita Therapeutics	N/A	N/A	N/A
BriaCell Therapeutics	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings and price targets for Crescita Therapeutics and BriaCell Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescita Therapeutics	0	0	0	0	N/A
BriaCell Therapeutics	0	0	0	0	N/A

Summary

Crescita Therapeutics beats BriaCell Therapeutics on 3 of the 3 factors compared between the two stocks.

BriaCell Therapeutics vs. Kane Biotech Stock

Kane Biotech (CVE:KNE) and BriaCell Therapeutics (CVE:BCT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Earnings and Valuation

This table compares Kane Biotech and BriaCell Therapeutics' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kane Biotech	C$1.34 million	12.95	C$-3,801,490.00	C($0.04)	-4.57
BriaCell Therapeutics	N/A	N/A	N/A	C($3.10)	-1.29

BriaCell Therapeutics has lower revenue, but higher earnings than Kane Biotech. Kane Biotech is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Kane Biotech and BriaCell Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kane Biotech	N/A	N/A	N/A
BriaCell Therapeutics	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings and price targets for Kane Biotech and BriaCell Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kane Biotech	0	0	0	0	N/A
BriaCell Therapeutics	0	0	0	0	N/A

Summary

Kane Biotech beats BriaCell Therapeutics on 2 of the 3 factors compared between the two stocks.

BriaCell Therapeutics vs. Devonian Health Group Stock

Devonian Health Group (CVE:GSD) and BriaCell Therapeutics (CVE:BCT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Earnings and Valuation

This table compares Devonian Health Group and BriaCell Therapeutics' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Devonian Health Group	C$1.59 million	15.20	C$-4,457,184.00	C($0.05)	-5.42
BriaCell Therapeutics	N/A	N/A	N/A	C($3.10)	-1.29

BriaCell Therapeutics has lower revenue, but higher earnings than Devonian Health Group. Devonian Health Group is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Devonian Health Group and BriaCell Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Devonian Health Group	N/A	N/A	N/A
BriaCell Therapeutics	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings and price targets for Devonian Health Group and BriaCell Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Devonian Health Group	0	0	0	0	N/A
BriaCell Therapeutics	0	0	0	0	N/A

Summary

Devonian Health Group beats BriaCell Therapeutics on 2 of the 3 factors compared between the two stocks.

BriaCell Therapeutics vs. Pascal Biosciences Stock

Pascal Biosciences (CVE:PAS) and BriaCell Therapeutics (CVE:BCT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Pascal Biosciences and BriaCell Therapeutics' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pascal Biosciences	N/A	N/A	N/A	C($0.02)	-4.32
BriaCell Therapeutics	N/A	N/A	N/A	C($3.10)	-1.29

Pascal Biosciences is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Pascal Biosciences and BriaCell Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pascal Biosciences	N/A	N/A	N/A
BriaCell Therapeutics	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for Pascal Biosciences and BriaCell Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pascal Biosciences	0	0	0	0	N/A
BriaCell Therapeutics	0	0	0	0	N/A

BriaCell Therapeutics vs. Naturally Splendid Enterprises Stock

Naturally Splendid Enterprises (CVE:NSP) and BriaCell Therapeutics (CVE:BCT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Naturally Splendid Enterprises and BriaCell Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Naturally Splendid Enterprises	0	0	0	0	N/A
BriaCell Therapeutics	0	0	0	0	N/A

Profitability

This table compares Naturally Splendid Enterprises and BriaCell Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Naturally Splendid Enterprises	N/A	N/A	N/A
BriaCell Therapeutics	N/A	N/A	N/A

Earnings & Valuation

This table compares Naturally Splendid Enterprises and BriaCell Therapeutics' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Naturally Splendid Enterprises	C$2.03 million	6.45	C$-9,371,678.00	C($0.04)	-1.40
BriaCell Therapeutics	N/A	N/A	N/A	C($3.10)	-1.29

BriaCell Therapeutics has lower revenue, but higher earnings than Naturally Splendid Enterprises. Naturally Splendid Enterprises is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Naturally Splendid Enterprises beats BriaCell Therapeutics on 2 of the 3 factors compared between the two stocks.

BriaCell Therapeutics vs. Medicure Stock

Medicure (CVE:MPH) and BriaCell Therapeutics (CVE:BCT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Earnings & Valuation

This table compares Medicure and BriaCell Therapeutics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicure	C$12.71 million	1.30	C$-16,188,599.00	C($1.55)	-1.02
BriaCell Therapeutics	N/A	N/A	N/A	C($3.10)	-1.29

BriaCell Therapeutics has lower revenue, but higher earnings than Medicure. BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Medicure, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Medicure and BriaCell Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicure	0	0	0	0	N/A
BriaCell Therapeutics	0	0	0	0	N/A

Profitability

This table compares Medicure and BriaCell Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medicure	N/A	N/A	N/A
BriaCell Therapeutics	N/A	N/A	N/A

Summary

Medicure beats BriaCell Therapeutics on 3 of the 3 factors compared between the two stocks.